Week in Review: Acletis Raising $457 Million in Hong Kong IPO at $2 Billion Valuation

00:12 EDT 22 Jul 2018 | ChinaBio Today

Deals and Financings

Trials and Approvals

Shanghai Green Valley Pharma reported "significantly improved" scores on assessment scales in Alzehimer's patients after a China Phase III trial of its seaweed-based treatment.

Stock Symbols: (SHA: 600196; HK: 02196) (SHA: 600535) (NSDQ: MESO; ASX: MSB) (SHZ: 300009) (P: EOSI)

Share this with colleagues:

More From BioPortfolio on "Week in Review: Acletis Raising $457 Million in Hong Kong IPO at $2 Billion Valuation"